- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages ...

Brenig Therapeutics, Inc. (Brenig), a clinical-stage biotechnology company advancing small-molecule therapies for neurodegenerative diseases, today announced the initiation of a first-in-human (FIH) ...

Expansion of lead KIF18Ai program in lung, head and neck cancers following early positive resultsGenetic biomarker signatures show early correlation with KIF18Ai clinical responseCompany reports ...

Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...

Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...

CALM has announced it is undergoing a significant reorganization of its clinical leadership structure aimed at improving consistency and staff support across the organization. The new leadership ...